Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.49 |
| ▸ | RAF1 | P04049 | 3/20 | 0.49 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.47 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5057550 | 0.91 | BRAF (0.61) | BRAFRAF1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL5062510 | 0.89 | KCNJ6 (0.49) | BRAFRAF1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL5065309 | 0.85 | BRAF (0.63) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL5061391 | 0.84 | MAPK14 (0.51) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL4430966 | 0.83 | BRAF (0.56) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL5065364 | 0.83 | MAPK14 (0.53) | BRAFMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4420251 | 0.81 | BRAF (0.44) | BRAFRAF1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL4417370 | 0.80 | BRAF (0.60) | BRAFRAF1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL5061852 | 0.80 | KCNJ6 (0.49) | BRAFRAF1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL5062767 | 0.79 | BRAF (0.47) | BRAFRAF1KCNJ6KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | claimed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | BRAF 1/4885RAF1 3/4885KCNJ6 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.